novo nordisk septerna

News

Novo Nordisk's latest bet on obesity pills

Novo Nordisk, U.S. biotech company team up to create obesity pills

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

The Wall Street Journal on MSN · 1d

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Seeking Alpha · 4h

Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

PMLive9h

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

11h

Septerna, Inc.: Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Novo Nordisk's latest bet on obesity pills

Trending now